Earli: Funding, Investors & Team (Oct 2026)
Earli’s mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
Earli has raised $40.0M across 1 funding round on record, the most recent a Series A of $40.0M announced in Jan 2021.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Earli Company Profile and Key Stats
Latest funding round on record: Jan 2021.
Earli Funding Rounds
Earli Founders and Leadership Team
Contact details for the Earli team: 1 of 1 has an email address on file.
Start 14-day free trial →Earli Funding Compared to Other Biotechnology Startups
Earli's latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Earli in Biotechnology and South San Francisco
Companies Similar to Earli
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Earli Funding FAQs
What does Earli do?
Earli’s mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
How much funding has Earli raised?
Earli has raised $40.0M across 1 round on record. The most recent is a Series A of $40.0M announced in Jan 2021.
When did Earli last raise funding?
Earli's most recent funding round on record is a Series A of $40.0M, announced in Jan 2021.
Who is the CEO of Earli?
Cyriac Roeding is listed as CEO at Earli.
Where is Earli headquartered?
Earli is based in South San Francisco, California, United States.
How many employees does Earli have?
Earli is in the 11-50 employee band.
How does Earli's funding compare to other Biotechnology startups?
Earli's latest round of $40.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Earli Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Earli is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.